Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Confirmatory Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia (Phase III Study).
Phase of Trial: Phase III
Latest Information Update: 16 Feb 2017
At a glance
- Drugs Lurasidone (Primary) ; Risperidone
- Indications Schizoaffective disorder; Schizophrenia
- Focus Registrational; Therapeutic Use
- Sponsors Sumitomo Dainippon Pharma
- 11 May 2011 Primary endpoint 'Positive-and-Negative-Syndrome-Scale' has not been met.
- 28 Feb 2009 Actual initiation date (July 2008) added as reported by ClinicalTrials.gov.
- 28 Feb 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History